Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.

①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.

cls.cn21:06 ET

Cisen Pharmaceutical's sales volume of the winning varieties in the centralized procurement has increased significantly. It is predicted that the sales of the large infusion sector will trend towards stability in the second half of the year. | Live from t

①At the earnings conference, the director of Cisen Pharmaceutical, Xu Xinbing, explained the gross margin and revenue decline of the company in the first half of the year. ②Xu Xinbing said that the company's sales volume of four varieties that were awarded in the eighth batch of centralized procurement showed a significant year-on-year increase. ③Du Zhenxin, the chairman of the company, introduced the company's development of generic drugs and innovative drugs.

cls.cnSep 9 05:55 ET

Zhejiang Hisun Pharmaceutical: Give up the pharmaceutical distribution raw material business, leading to a decline in H1 revenue. Sales of Olsalazine increased significantly compared to the same period last year.

①At the earnings conference, the CFO of Zhejiang Hisun Pharmaceutical explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution raw material business and other factors. ②President Xiao Weihong addressed questions about the growth in endocrine drug revenue and the future business model of the animal health sector.

cls.cnSep 4 09:29 ET

chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.

① Chongqing Zhifei Biological Products 23-valent pneumococcal polysaccharide vaccine has lowered its online price by nearly 30% in provinces such as Jiangsu and Jilin; ② Currently, China's pneumococcal vaccine market is showing a competitive situation of "wrestling" between overseas MNCs and domestic companies, and more and more companies are expanding their presence in this field; ③ Industry experts believe that in order to occupy the market, companies can only choose to actively reduce prices.

cls.cnSep 4 07:55 ET

The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.

Due to the decrease in sales volume of H1's main products, Chongqing Zhifei Biological Products reported a decrease in revenue and net income in its semi-annual report. The volume of Merck's quadrivalent HPV vaccine, which the company represents, decreased by more than 90% compared to the previous year. With the accelerated development of domestically-produced nine-valent HPV vaccines, the company's pressure will further increase.

cls.cnAug 29 11:32 ET

The recovery of the live pig market, ST Tianbang H1 turns loss into profit, and the pre-reorganization progresses as the company's debt decreases | interpretations

①ST Tianbang achieved a net profit of 0.174 billion yuan after non-deductible adjustments in Q2, compared to a net loss of 0.455 billion yuan after non-deductible adjustments for the company in Q1, indicating a significant improvement in the main business performance; ②During the reporting period, the company's food business grew significantly, but it remained in a loss state; ③The company made certain progress in reducing its debt, with total debt decreasing by 3.577 billion yuan since the beginning of the year and the debt ratio decreasing by 8.33 percentage points.

cls.cnAug 29 11:04 ET